The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SITC 2021 | Discovering immunotherapy resistance mechanisms using single-cell technologies
Zinaida Good, PhD, Stanford University, Stanford, CA, talks on the use of single-cell technologies to decipher the mechanisms of resistance to chimeric antigen receptor (CAR) T-cell therapy. Dr Good explains that measuring a large number of markers provides a better understanding of these mechanisms. For instance, a marker of T-cell senescence, CD57, was included in a recent study investigating which intrinsic features of CAR T-cells correlated with durable response, and unexpectedly emerged as the strongest association with treatment response. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
